Here's Why F5 Networks (FFIV) is a Strong Growth Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.
While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.
For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.
Seattle, WA-based F5 Networks Inc, founded in 1996, provides products and services to manage Internet traffic worldwide. Its application, delivery and networking products improve performance, availability and security of applications running on networks that use the Internet Protocol (IP).
FFIV boasts a Growth Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 8.8% year-over-year for 2025, while Wall Street anticipates its top line to improve by 7%.
Seven analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.22 to $14.55 per share. FFIV also boasts an average earnings surprise of 11%.
On a historic basis, F5 Networks has generated cash flow growth of 5.1%, and is expected to report cash flow expansion of 16.7% this year.
With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, FFIV should be on investors' short lists.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
F5, Inc. (FFIV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
M&A News: Nvidia (NVDA) Acquires AI Startup CentML
Chipmaker Nvidia (NVDA) has acquired Toronto-based AI startup CentML, according to The Logic, which is a major win for the startup and its investors. Interestingly, LinkedIn profiles show that CentML CEO Gennady Pekhimenko has taken on a senior director role for AI software at Nvidia, while the startup's CTO and COO also joined in managerial positions. In total, at least 15 engineers and two interns from CentML have joined Nvidia this month, the report added. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter It is worth noting that CentML, founded in 2022, focused on helping companies run AI systems more efficiently by optimizing how models use hardware resources. The startup had raised about $30.9 million in venture capital, including a $27 million seed round that Nvidia participated in last year. CentML was also part of Nvidia's accelerator program and had already been collaborating with the tech giant before the acquisition. As a result of the move, the company will stop offering services by July 17, according to a message posted in CentML's Slack channel and on X. Unfortunately, not all CentML employees are making the move to Nvidia, as some roles were cut due to an 'organizational restructuring.' This included CentML dissolving its federal incorporation and re-registering under British Columbia law in early June. Meanwhile, Nvidia continues its upward momentum, with shares gaining nearly 17% year-to-date and rising again on Friday. With a market cap of about $3.78 trillion, analysts at Wedbush believe that Nvidia could hit $4 trillion this year and possibly reach $5 trillion within the next 18 months as the AI boom accelerates. What Is a Good Price for NVDA? Turning to Wall Street, analysts have a Strong Buy consensus rating on NVDA stock based on 35 Buys, four Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average NVDA price target of $175.28 per share implies 11.6% upside potential.
Business Upturn
4 hours ago
- Business Upturn
Sage Healthspan Launches AI-Powered, Privacy-First Wellness App to Bridge Critical Gaps in Preventative Healthcare
Orange County, California, June 27, 2025 (GLOBE NEWSWIRE) — Sage Healthspan, a California-based digital health company, announced its precision health app, now available for free on Apple's App Store. Designed to address notable shortcomings in modern healthcare delivery, Sage introduces a privacy-first, on-device artificial intelligence (AI) platform aimed at helping users interpret their blood work, monitor health trends, and optimize wellness without sacrificing data security. A Glimpse into Sage Healthspan Analytic Features In an era where preventative healthcare is increasingly prioritized, many individuals still lack access to timely, comprehensible, and actionable insights from their routine lab results. Sage Healthspan identified a persistent issue: although patients regularly undergo blood tests, most are only contacted if major abnormalities are flagged. This approach overlooks nuanced health patterns and early indicators of disease, leading to missed opportunities for early intervention. 'Instead of waiting for symptoms to appear, Sage empowers users to engage proactively with their health data,' said Megan Haas, Media and Communications Lead at Sage Healthspan. 'The AI platform helps transform routine lab work into structured insights, encouraging users to take control of their health trajectory in a secure, comprehensible, and private way.' Closing the Loop Between Data and Action Sage allows users to upload or photograph existing lab results directly from their Apple devices. The platform then interprets the data using local AI algorithms, never uploading personal information to the cloud, providing summaries, visualizations, and tailored recommendations. This includes suggestions for lifestyle adjustments, supplement considerations, or follow-up testing to support long-term wellness goals. Importantly, Sage differentiates itself by emphasizing a 'privacy-first' model. All health data remains on the user's device, enabling secure HIPAA-compliant analysis. In a climate where 78% of healthcare executives name cybersecurity as a top priority, Sage's on-device processing offers a practical alternative to cloud-based health apps. A Comprehensive Health Insight Engine Sage's AI generates insights across an extensive array of health and biomarker categories, including cardiometabolic health, inflammation, blood sugar, autoimmunity, nutrient status, thyroid health, kidney and liver function, and more. As users contribute additional data over time, Sage builds a personalized timeline, allowing for trend detection and wellness optimization rooted in longitudinal analysis. A unique feature of Sage's platform is its lab test ordering capability. Users can independently request advanced biomarkers that are often excluded from standard panels. These include cardiovascular indicators such as ApoB and Lp(a), fasting insulin and HOMA-IR for metabolic health, thyroid and sex hormone assessments, and nutritional markers like vitamin D and omega-3 fatty acid levels. The Growing Importance of Intelligent Health Analytics Recent studies show that 67% of patients report confusion over their lab results, with 61% struggling to understand medical terminology. Additionally, with primary care visits averaging only 15-18 minutes, providers have limited time to address complex, individualized wellness concerns. Sage Healthspan aims to complement, not replace, medical professionals by offering supportive tools that clarify and contextualize lab data for users. From a broader healthcare systems perspective, early detection is increasingly recognized as a critical cost-saver. Nearly 90% of the United States' annual $4.5 trillion healthcare expenditure is tied to chronic conditions. Sage's focus on biomarker-based early detection aligns with evolving industry goals: identifying risk before symptoms arise and enabling targeted, timely action. Positioning in the Era of Medicine 3.0 The emergence of AI in health represents a shift toward what experts call 'Medicine 3.0,' a paradigm that emphasizes prevention, personalization, and patient empowerment. Sage Healthspan embodies this transition. By integrating intelligent health analytics into everyday devices and eliminating the need for cloud computing, the company delivers accessible wellness insights while maintaining robust privacy protections. Sage Healthspan is currently available exclusively for iOS on Apple's App Store. Users are encouraged to begin by uploading pre-existing lab results to generate immediate health insights. For more information or to learn how Sage can support a wellness journey, visit About Sage Healthspan Sage Healthspan is a health technology company based in California focused on closing critical gaps in preventative healthcare. Through its privacy-first AI app, Sage empowers users to understand and act on their blood work, providing structured insights across a range of biomarkers to support health optimization and early detection. Sage's core mission is to make personalized wellness both accessible and secure. Sage Healthspan Logo Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Insider
4 hours ago
- Business Insider
Cofounder of Neuralink rival Precision Neuroscience reveals what people often get wrong about brain implants
At least that's the line from Dr. Ben Rapoport, the cofounder and chief science officer of Precision Neuroscience, a brain-computer interface, or BCI, company. "Many people have the impression that the data that we care about is sort of everywhere inside this dimensional structure," Rapoport, a neurosurgeon and engineer, told Business Insider. That's a big misconception, he said. People often incorrectly assume that "you need electrodes that penetrate deep inside the brain to get that information out," he added. But brain implants don't need to be as invasive as they might sound, he said. Precision is developing a thin film that sits on the brain and records brain activity in patients with paralysis. "We implant modules of 1,024 electrodes on the brain surface in the area that controls movement, especially the hand," Rapoport said. That allows them to have cursor control, typing ability, access the internet, use PowerPoint, play games, and word process, he added. These are actions that require vision, movement, sensation, and executive function — core parts of consciousness that are concentrated in the brain's outermost layer, the cortex, Rapoport said. Deeper inside are "connections, you know, between those activities and also sort of subconscious processes, because the brain coordinates a lot of activities in the body that don't take place consciously," he added. The New York-based startup, which received FDA clearance for part of its wireless brain-computer interface in April, has raised $155 million in funding since it launched in 2021. It is one of a few companies advancing this technology as part of the Implantable BCI Collaborative Community. BCIs are largely classified into two categories: invasive and non-invasive. Non-invasive BCIs, which don't require surgery, often rely on external sensors to detect the electrical signals in the brain. BCS that are implanted record neural activity directly from the brain and are being developed to restore speech, movement, and other complex functions in people with neurological conditions. The buzziest BCI these days is Elon Musk's Neuralink, which has ambitions to create a "symbiosis" between the human brain and AI. But there are a host of other companies working on BCIs as a way to treat neurological diseases, like Precision Neuroscience. The company has tested its temporary device in over forty patients in early clinical studies. Over the next year, it will prepare for the first human studies of its permanently implanted devices. "There are certain internal validation checks and internal milestones that we need to meet for ourselves and for the FDA before we want to start implanting the permanently implanted wireless device in humans," Rapoport said. The company's ultimate goal is to help paralyzed people get "back to a level of functional capacity where they can be significantly independent, economically self-sufficient, and hold a job in the workplace," Rapoport said. Correction: June 27, 2025 — An earlier version of this story said that Dr. Ben Rapoport was the founder and CEO of Precision Neuroscience; Dr. Rapoport is the cofounder and chief science officer. An earlier version also mischaracterized the film that goes on the brain. It is not studded with electrodes; the electrodes are embedded.
